Market research
EVL.F Evolus, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 469M
- P/E ratio
- Not available
- Analyst target
- 17.14
- Dividend yield
- Not available
- Beta
- 1.36
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US30052C1071
- Market cap
- 469M
- P/E ratio
- Not available
- Analyst target
- 17.14
- Dividend yield
- Not available
- Beta
- 1.36
About
About Evolus, Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVL.F discussion.
5 years, 5 months ago
Evolus, Inc is currently in a long term uptrend where the price is trading 61.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.
Evolus, Inc's total revenue rose by 5.8% to $21M since the same quarter in the previous year.
Its net income has dropped by 663.0% to $-111M since the same quarter in the previous year.
Finally, its free cash flow grew by 86.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Evolus, Inc gets an overall score of 4/5.